Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 3, 2013, Pages 347-351

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Merriam, C Vreni ^a   Tyrrell, Kerin L ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anaerobes; Avibactam; Bacteroides fragilis; Ceftaroline; Diabetic foot infections; Finegoldia magna; MRSA

Indexed keywords

AVIBACTAM; CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; ERTAPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

AEROBIC BACTERIUM; AGAR DILUTION; ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; BROTH DILUTION; CLOSTRIDIA; COMPARATIVE EFFECTIVENESS; DIABETIC FOOT; DIABETIC FOOT INFECTION; DISEASE SEVERITY; ENTEROCOCCUS; HUMAN; IN VITRO STUDY; INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTEROIDES FRAGILIS; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; DIABETES COMPLICATIONS; DRUG SYNERGISM; ENTEROBACTER; FOOT DISEASES; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MORGANELLA; PREVOTELLA;

EID: 84879155354     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.03.019     Document Type: Article

References (17)

1. Al B.K., Al M.A., Rotimi V.O. A study of the microbiology of diabetic foot infections in a teaching hospital in Kuwait. J Infect Public Health 2012, 5:1-8.
2. Castanheira M., Sader H.S., Farrell D.J., Mendes R.E., Jones R.N. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother 2012, 56:4779-4785.
3. Centers for Disease Control and Prevention (CDC) National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States http://www.cdc.gov./diabetes/pubs/pdf/ndfs_2011.pdf.
4. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819-2828.
5. Citron D.M., Tyrrell K.L., Merriam C.V., Goldstein E.J. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010, 54:1627-1632.
6. Citron D.M., Tyrrell K.L., Merriam V., Goldstein E.J. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother 2011, 55:3616-3620.
7. Clinical and Laboratory Standards Institute (CLSI) Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-eighth edition, M11-A8 2012, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition, M7-A9 2012, CLSI, Wayne, PA.
9. Ehmann D.E., Jahic H., Ross P.L., Gu R.F., Hu J., Kern G., et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A 2012, 109:11663-11668.
10. Gadepalli R., Dhawan B., Sreenivas V., Kapil A., Ammini A.C., Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 2006, 29:1727-1732.
11. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006, 50:3959-3962.
12. Lipsky B.A., Berendt A.R., Cornia P.B., Pile J.C., Peters E.J., Armstrong D.G., et al. Executive summary: 2012. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012, 54:1679-1684.
13. Lipsky B.A., Pecoraro R.E., Larson S.A., Hanley M.E., Ahroni J.H. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990, 150:790-797.
14. Lipsky B.A., Tabak Y.P., Johannes R.S., Vo L., Hyde L., Weigelt J.A. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 2010, 53:914-923.
15. Saravolatz L.D., Stein G.E., Johnson L.B. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011, 52:1156-1163.
16. Tascini C., Piaggesi A., Tagliaferri E., Iacopi E., Fondelli S., Tedeschi A., et al. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy. Diabetes Res Clin Pract 2011, 94:133-139.
17. Weigelt J.A. Diabetic foot infections: diagnosis and management. Surg Infect (Larchmt) 2010, 11:295-298.